Cancer - Pyxis Oncology, Inc.

Cancer

Status:

Active, open to accrual

ClinicalTrials.gov:

NCT05718557

A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PYX 106 in Subjects with Advanced Solid Tumors

Drug

PYX-106

Condition

non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer (BC), endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma (CCA), bladder cancer, colorectal cancer (CRC), and head and neck squamous cell carcinoma